Evaluation of the Lung Clearance Index (LCI)
Primary Purpose
Cystic Fibrosis
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Lung clearance index determination
Sponsored by
About this trial
This is an interventional screening trial for Cystic Fibrosis focused on measuring Cystic fibrosis,, lung clearance index,, pulmonary function
Eligibility Criteria
Inclusion Criteria:
- Children with typical cystic fibrosis (sweat chloride level >60 mEq/l) followed in reference centre participating to the study
- From 3 to 6 years old
- Children with a planned annual assessment that required thoracic computed tomography and lung function test
- Children with informed and non opposed parents
Exclusion Criteria:
- Children with atypical cystic fibrosis
- Children with bronchial exacerbation dating less than 2 weeks
- Children with severe associated disease
Sites / Locations
- Hôpital Necker-Enfants Malades
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
LCI
Arm Description
Measure of lung clearance index
Outcomes
Primary Outcome Measures
measure of nitrogen washout and Brody 2 score
Secondary Outcome Measures
measure of FEV (Correlation between the evolution of LCI and respiratory function endpoints and CT)
Correlation between the evolution of LCI and respiratory function endpoints and CT
measure of FEV (Evaluation of LCI predictive value for respiratory function in preschool children)
Evaluation of LCI predictive value for respiratory function in preschool children.
Full Information
NCT ID
NCT02342951
First Posted
August 7, 2014
Last Updated
October 18, 2019
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Vaincre la Mucoviscidose
1. Study Identification
Unique Protocol Identification Number
NCT02342951
Brief Title
Evaluation of the Lung Clearance Index
Acronym
LCI
Official Title
Evaluation of Lung Clearance Index for Early Detection of Lung Disease in Young Children With Cystic Fibrosis
Study Type
Interventional
2. Study Status
Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
April 2014 (Actual)
Primary Completion Date
April 2019 (Actual)
Study Completion Date
July 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Vaincre la Mucoviscidose
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine the efficacy of a non invasive method of detecting the pulmonary disease in order to initiate treatment against cystic fibrosis as soon as possible.
Moreover this screening procedure permits to note the improvement following the treatment and to choose the optimal treatment in term of efficacy.
Detailed Description
It is mandatory to detect as early as possible lung CF disease in the young child with CF to initiate active therapies limiting irreversible lesions. Lung Clearance Index (LCI) which evaluates gas clearance from the alveolar volume is an easy to-do technique in pre-school children.
Main objective To evaluate correlation between LCI and thoracic low dose computed tomodensitometry (CT) endpoints at initial visit Secondary objectives
To evaluate correlation between LCI and respiratory function measurements at each visit
To evaluate correlation between the evolution of LCI and respiratory function endpoints and the evolution of CT only for the children for whom a thoracic low dose CT is requested by their referent doctor after two years.
To evaluate LCI predictive value for respiratory function 2 years later in preschool children.
This is a prospective multicenter cohort study. Study visits will be performed each year during the annual check up for normal follow up of the child.
Initial visit (Visit 1) takes place during an annual check-up during which a low dose CT was prescribed. It will include following tests: LCI, Lung function tests (LFTs) performed according to age (forced volumes and flows, plethysmographic specific airway resistances and interrupter resistances), and a low dose CT scan performed according a standardized protocol.
Visit 2 will be performed 12 ± 3 months later and will include following tests: LCI , LFTs.
Visit 3 will be performed 24 ± 3 months later and will include following tests: LCI , LFTs and, if judged necessary by the child's referent doctor, a low dose CT scan performed according to a standardized protocol.
Anthropometric data, infection history, treatment will be collected at each visit.
Recruiting period: 1 year Study period: 2 years per patient, 3 years as a whole LCI will help to evaluate early ventilation inhomogeneity due to small bronchi abnormalities in young children with CF. Concordance between LCI and CT endpoints evaluation will help to define the frequency of lung CT administration in young CF children. Predictive value for later abnormal lung function development will be evaluated. This will help to detect the children at risk to develop abnormal lung function and to target those requiring active treatment. Finally this endpoint will be very valuable in the future therapeutic trials for CFTR correctors or potentiators.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cystic Fibrosis
Keywords
Cystic fibrosis,, lung clearance index,, pulmonary function
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
53 (Actual)
8. Arms, Groups, and Interventions
Arm Title
LCI
Arm Type
Other
Arm Description
Measure of lung clearance index
Intervention Type
Other
Intervention Name(s)
Lung clearance index determination
Intervention Description
Lung clearance index determination
Primary Outcome Measure Information:
Title
measure of nitrogen washout and Brody 2 score
Time Frame
Month 0
Secondary Outcome Measure Information:
Title
measure of FEV (Correlation between the evolution of LCI and respiratory function endpoints and CT)
Description
Correlation between the evolution of LCI and respiratory function endpoints and CT
Time Frame
2 years
Title
measure of FEV (Evaluation of LCI predictive value for respiratory function in preschool children)
Description
Evaluation of LCI predictive value for respiratory function in preschool children.
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
3 Years
Maximum Age & Unit of Time
6 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Children with typical cystic fibrosis (sweat chloride level >60 mEq/l) followed in reference centre participating to the study
From 3 to 6 years old
Children with a planned annual assessment that required thoracic computed tomography and lung function test
Children with informed and non opposed parents
Exclusion Criteria:
Children with atypical cystic fibrosis
Children with bronchial exacerbation dating less than 2 weeks
Children with severe associated disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Muriel Le Bourgeois, MD
Organizational Affiliation
Service de pneumologie pédiatrique, Hôpital Necker-Enfants Malades Assistance Publique Hôpitaux de Paris 75015 Paris, France
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôpital Necker-Enfants Malades
City
Paris
ZIP/Postal Code
75015
Country
France
12. IPD Sharing Statement
Learn more about this trial
Evaluation of the Lung Clearance Index
We'll reach out to this number within 24 hrs